Indian Emulsifiers missed its margin guidance, but the real problem is the rights issue math
Revenue grew 57% to ₹160 cr, but EBITDA margin fell to 16.4% versus an 18-22% guide. Now it wants shareholders to fund a ₹51 cr raise when the company is worth ₹75 cr.
What's new
- FY26 revenue hit ₹159.87 cr, up 57% year-on-year, but well below the 100% growth guidance issued earlier.
- EBITDA margin compressed to 16.4% versus the guided 18-22%, a miss of 200-350 basis points.
- Board approved a second rights issue in principle, pending exchange approval; pricing and size not finalized.
- Chemical Brothers consolidation aims to bring in a major customer expected to deliver ₹1-1.5 cr in near-term revenue.
Themes from the call
Margins
Management deliberately sacrificed margin for volume, prioritizing customer deepening. EBITDA margin missed guidance by 200-350 bps as debtor days stretched from 110 to 131.
Capital allocation
A new rights issue is pending. The combined raise of ~₹51 cr is being pursued when the company's market cap is only ~₹75 cr, implying 68% dilution to existing shareholders.
Capacity
Current capacity is 1,000 tons/month, but complex product mix means some lines are at maximum efficiency. A greenfield plant is expected by end-FY27, adding 400-500 tons/month.
Guidance watch
- FY26 revenue guidance of 100% growth was missed (achieved 57%); management attributed the miss to geopolitical shocks and raw material inflation in February-March.
- EBITDA margin guidance of 18-22% was missed (achieved 16.4%); management framed the compression as a deliberate strategic choice for long-term volume.
- Second rights issue terms are pending exchange approval; no pricing, size, or timeline finalized.
Risk flags
- Shareholder dilution is severe. At a ₹75 cr market cap, a ₹51 cr raise implies existing holders' stake is cut by over two-thirds.
- The Chemical Brothers acquisition involves a related party, and the full consolidation plan via merger or share swap introduces execution and governance risk.
- Working capital balloon to ₹50.73 cr from ₹36.31 cr is tying up cash as debtor days extend.
Key quotes
-
"Because of Chemical Brothers, a big customer visited Indian Emulsifiers last month. That customer is going to give business of 1 to 1.5 crores to Indian Emulsifiers within the next couple of months."
— Yash Thakkar, MD -
"MD committed to participate in new rights to best of ability similar to prior round but acknowledged limited personal resources."
— AI Summary of MD's comments
The brief
Indian Emulsifiers delivered 57% revenue growth in FY26. That sounds strong until you remember management guided for 100%. The miss came from geopolitical and raw material shocks in February-March, according to the MD. But the bigger issue for shareholders isn't the top line. It's the margin, and the fundraise. EBITDA margin landed at 16.4%, well below the 18-22% guide. Management framed this as a deliberate trade-off, sacrificing near-term rate for customer deepening and volume. Debtor days stretched from 110 to 131, and working capital ballooned to ₹50.73 cr from ₹36.31 cr.
The capital structure is now the dominant concern. The board has approved a second rights issue in-principle, pending exchange clearance. This comes just six months after the prior fundraise. At a current market cap of roughly ₹75 cr, the ₹51 cr raise implies 68% dilution. The promoter has pledged to participate but admits limited personal resources. Promoter holding has already fallen from 48% to 32%. The funds are earmarked for capacity expansion and the consolidation of Chemical Brothers, a related-party trading company.
The Chemical Brothers deal is positioned as a customer acquisition play. A major customer is expected to bring in ₹1-1.5 cr in business within months, purely on the strength of a decade-old trading relationship. But the related-party nature of the transaction and the multi-step consolidation plan via merger or share swap add governance complexity.
Capacity is growing. A new greenfield plant is targeted for end-FY27, adding 400-500 tons per month to the existing 1,000. An adjoining facility for food-grade certification is expected by early FY28. But the current plant is running at or above maximum efficiency on some lines, meaning the new capacity isn't a nice-to-have. It's a requirement. The question is whether the dilution is worth it for shareholders who are already sitting on steep losses.
Growth at Indian Emulsifiers is real. The price shareholders are being asked to pay for it is getting steep.